Earlier answers for neurology trials

FBB’s RNA Systems Intelligence platform shows drug developers how a therapy changes each trial participant’s regulatory biology, earlier than clinical endpoints can. The platform only needs one extra tube at an existing blood draw.

Next provisional patent filed

Non-coding RNA expression in the blood reflects which regulatory genes are overactive or underactive. FBB Biomed's proprietary analytics platform uses RNA-sequencing data to quantify this activity across the biological systems underlying a patient's condition. An upstream, systems-level readout no other platform delivers.

Decoding chronic disease with RNA systems biology

Who it's for

Biopharma

Stratify trial participants and monitor individual response with signal from regulatory genes

Labs

Develop blood liquid biopsies for neurology on existing RNA-sequencing infrastructure

FBB Biomed's platform is currently available for research use only.

Inquiries: info@FBBbio.com

2500 Crosspark Road, UI BioVentures Center

Coralville, Iowa 52241, USA